RT Journal Article
SR Electronic
T1 Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.16.21267902
DO 10.1101/2021.12.16.21267902
A1 Abu-Raddad, Laith J.
A1 Chemaitelly, Hiam
A1 Ayoub, Houssein H.
A1 Yassine, Hadi M.
A1 Benslimane, Fatiha M.
A1 Al Khatib, Hebah A.
A1 Tang, Patrick
A1 Hasan, Mohammad R.
A1 Coyle, Peter
A1 Kanaani, Zaina Al
A1 Kuwari, Einas Al
A1 Jeremijenko, Andrew
A1 Kaleeckal, Anvar Hassan
A1 Latif, Ali Nizar
A1 Shaik, Riyazuddin Mohammad
A1 Abdul Rahim, Hanan F.
A1 Nasrallah, Gheyath K.
A1 Al Kuwari, Mohamed Ghaith
A1 Butt, Adeel A.
A1 Al Romaihi, Hamad Eid
A1 Al-Thani, Mohamed H.
A1 Khal, Abdullatif Al
A1 Bertollini, Roberto
YR 2021
UL http://medrxiv.org/content/early/2021/12/16/2021.12.16.21267902.abstract
AB BACKGROUND In early 2021, Qatar launched a mass immunization campaign with Moderna’s mRNA-1273 COVID-19 vaccine. We assessed persistence of real-world mRNA-1273 effectiveness against SARS-CoV-2 infection and against COVID-19 hospitalization and death.METHODS Effectiveness was estimated using test-negative, case-control study design, between January 1 and December 5, 2021. Effectiveness was estimated against documented infection (a PCR-positive swab, regardless symptoms), and against any severe (acute-care hospitalization), critical (ICU hospitalization), or fatal COVID-19.RESULTS By December 5, 2021, 2,962 breakthrough infections had been recorded among those who received two mRNA-1273 doses. Of these infections, 19 progressed to severe COVID-19 and 4 to critical, but none to fatal disease. mRNA-1273 effectiveness against infection was negligible for the first two weeks after the first dose, increased to 65.5% (95% CI: 62.7-68.0%) 14 or more days after the first dose, and reached its peak at about 90% in the first three months after the second dose. Effectiveness declined gradually starting from the fourth month after the second dose and was below 50% by the 7th month after the second dose. Effectiveness against severe, critical, or fatal COVID-19 reached its peak at essentially 100% right after the second dose, and there was no evidence for declining effectiveness over time. Effectiveness against symptomatic versus asymptomatic infection demonstrated the same pattern of waning, but effectiveness against symptomatic infection was consistently higher than that against asymptomatic infection and waned more slowly.CONCLUSIONS mRNA-1273-induced protection against infection appears to wane month by month after the second dose. Meanwhile, protection against hospitalization and death appears robust with no evidence for waning for several months after the second dose.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. Statements made herein are solely the responsibility of the authors. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards with a waiver of informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.